133 related articles for article (PubMed ID: 17354204)
1. Polypeptide growth factors in gastroenteropancreatic neuroendocrine tumours.
Blicharz-Dorniak J; Kos-Kudła B; Kudła M; Foltyn W; Marek B; Siemińska L; Nowak M
Endokrynol Pol; 2007; 58(1):42-9. PubMed ID: 17354204
[TBL] [Abstract][Full Text] [Related]
2. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.
Wulbrand U; Wied M; Zöfel P; Göke B; Arnold R; Fehmann H
Eur J Clin Invest; 1998 Dec; 28(12):1038-49. PubMed ID: 9893017
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances.
Corleto VD; Delle Fave G; Jensen RT
Dig Liver Dis; 2002 Sep; 34(9):668-80. PubMed ID: 12405256
[TBL] [Abstract][Full Text] [Related]
4. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.
Kidd M; Modlin I; Öberg K
Nat Rev Clin Oncol; 2016 Nov; 13(11):691-705. PubMed ID: 27273044
[TBL] [Abstract][Full Text] [Related]
5. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
6. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
7. Nutrition and gastroenteropancreatic neuroendocrine tumors.
Go VL; Srihari P; Kamerman Burns LA
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):827-37. PubMed ID: 21095548
[TBL] [Abstract][Full Text] [Related]
8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours.
Cohen T; Herzog Y; Brodzky A; Greenson JK; Eldar S; Gluzman-Poltorak Z; Neufeld G; Resnick MB
J Pathol; 2002 Sep; 198(1):77-82. PubMed ID: 12210066
[TBL] [Abstract][Full Text] [Related]
10. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.
Reynolds AR; Kyprianou N
Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S144-52. PubMed ID: 16465179
[TBL] [Abstract][Full Text] [Related]
11. Implications of growth factor alterations in the treatment of pancreatic cancer.
Juhász M; Nitsche B; Malfertheiner P; Ebert MP
Mol Cancer; 2003 Jan; 2():5. PubMed ID: 12537586
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
13. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
[TBL] [Abstract][Full Text] [Related]
14. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
Grande E; Capdevila J; Barriuso J; Antón-Aparicio L; Castellano D
Cancer Metastasis Rev; 2012 Jun; 31(1-2):47-53. PubMed ID: 22105614
[TBL] [Abstract][Full Text] [Related]
16. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.
Vitale G; de Herder WW; van Koetsveld PM; Waaijers M; Schoordijk W; Croze E; Colao A; Lamberts SW; Hofland LJ
Cancer Res; 2006 Jan; 66(1):554-62. PubMed ID: 16397272
[TBL] [Abstract][Full Text] [Related]
17. Growth factors involved in aqueous humour-induced lens cell proliferation.
Iyengar L; Patkunanathan B; McAvoy JW; Lovicu FJ
Growth Factors; 2009 Feb; 27(1):50-62. PubMed ID: 19085197
[TBL] [Abstract][Full Text] [Related]
18. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
20. Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.
Carrasco P; Zuazo-Gaztelu I; Casanovas O
J Mol Endocrinol; 2017 Jul; 59(1):R77-R91. PubMed ID: 28469004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
